Another Paragon offshoot chooses reverse merger, this time for migraine drugs

May 19, 2026 02:56 PM EDT FinancingDeals An­oth­er Paragon off­shoot choos­es re­verse merg­er, this time for mi­graine drugs Kyle LaHucik Biotech Correspondent They say stick to what you know. And Paragon Ther­a­peu­tics knows how to do re­verse merg­ers. The hub-and-spoke bi­o­log­ics com­pa­ny is mov­ing its mi­graine drug … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER